Use of mutant Herpes Simplex Virus-2 for cancer therapy

Details for Australian Patent Application No. 2006262021 (hide)

International Classifications

Event Publications

21 February 2008 Amendment Made

The nature of the amendment is as shown in the statement(s) filed 09 Jan 2008

29 May 2008 Section 223 Application Received

Baylor College Of Medicine An application to extend the time from 04 Jan 2007 to 04 Feb 2008 in which to enter the National Phase has been filed . Address for service in Australia - FB Rice & Co Level 23 200 Queen St Melbourne VIC 3000 2007

17 July 2008 Section 223 Application Allowed

Baylor College Of Medicine The time in which to enter the National Phase has been extended to 04 Feb 2008. Address for service in Australia - FB Rice & Co Level 23 200 Queen St Melbourne VIC 3000

24 July 2008 PCT application entered the National Phase

PCT publication WO2007/002373 Priority application(s): WO2007/002373

10 June 2010 Assignment before Grant

Baylor College of Medicine The application has been assigned to The University of Houston

12 January 2012 Application for Amendment

The nature of the amendment is as shown in the statement(s) filed 15 Dec 2011. Address for service in Australia - FB Rice Level 23 200 Queen Street Melbourne VIC 3000

19 January 2012 Application Accepted

Published as AU-B-2006262021

10 May 2012 Amendment Made

The nature of the amendment is as shown in the statement(s) filed 15 Dec 2011

17 May 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.